TERT promoter mutations are present in approximately 55% of bladder cancers across all stages, while FGFR3 mutations are found in 30–50% of cases, often in low-grade, non-muscle-invasive tumors [42,57]. Here, FGFR3 is linked to urinary bladder carcinoma.